Dublin, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The "Germany: CBD and Cannabis Regulation" report has been added to ResearchAndMarkets.com's offering.
This report offers a detail analysis of the country's regulatory regime for hemp, cannabinoids including CBD, as well as medical and recreational cannabis
Cannabis - along with cannabis resin ("hashish, the separated resin of the plants of genus cannabis") - is classified as a scheduled substance according to Annex 1 of the German Narcotic and Psychotropic Drugs Act.
Recreational cannabis is expected to undergo major changes in the coming years. The government has presented the first draft law (hereinafter the Cannabis Act draft) in July 2023, allowing self-cultivation and non-commercial cultivation through cannabis clubs.
Key Topics Covered:
- Executive summary
- Outlook
- Hemp plant
- Extracts and synthetics
- Finished products containing CBD and extracts
- Import and export requirements
- Minor cannabinoids
- Medical cannabis
- Recreational cannabis
- Relevant laws
- Relevant bodies
For more information about this report visit https://www.researchandmarkets.com/r/brso31
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
